PD L1 News and Research

RSS

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

A combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase inhibitor, axitinib, significantly improves progression-free survival in previously untreated patients with advanced renal cell carcinoma in a phase 3 study, according to results presented at ESMO 2018 Congress.

22 Oct 2018

Immunotherapy increases survival in some patients with metastatic triple negative breast cancer

Immunotherapy improves survival in some patients with metastatic triple negative breast cancer, according to late-breaking results from the IMpassion130 trial reported at the ESMO 2018 Congress in Munich.

22 Oct 2018

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.

22 Oct 2018

First-of-its-kind study to test a personalized vaccine in cancer patient

Tamara Strauss has been living with high-grade, stage IV pancreatic neuroendocrine cancer for more than three years. Current treatments, although effective for her, are highly toxic.

15 Oct 2018

HalioDx announces availability of Brightplex, a high capacity IHC multiplex technology

HalioDx, an immuno-oncology company pioneering the immunological diagnosis of cancers, announces the availability of Brightplex, a novel high capacity IHC multiplex technology enabling multiple biomarkers to be analyzed on a single FFPE slide.

4 Oct 2018

New project identifies immune checkpoint inhibition as potential treatment for angiosarcomas

Angiosarcoma Project, a patient-partnered genomics study, identified immune checkpoint inhibition as a potential treatment option for patients with angiosarcomas of the head, face, neck, or scalp, according to data presented at the fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.

1 Oct 2018

FDA approves first intravenous treatment for metastatic cutaneous squamous cell carcinoma

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

28 Sep 2018

Non-small cell lung cancer patients survive longer when treated with durvalumab

Non-small cell lung cancer patients survive longer when their treatment includes durvalumab following platinum-based chemoradiotherapy, according to research led by Moffitt Cancer Center.

27 Sep 2018

Organs actively fighting back against autoimmune diseases, finds study

Organs affected by autoimmune disease could be fighting back by "exhausting" immune cells that cause damage using methods similar to those used by cancer cells to escape detection, according to a study by researchers at the University of Pittsburgh School of Medicine published today in the Journal of Clinical Investigation.

25 Sep 2018

Immune checkpoint inhibition may be effective in treating HIV-associated Kaposi's sarcoma

Among a small cohort of patients with HIV-associated Kaposi's sarcoma treated with immune checkpoint inhibitors, more than 65 percent had partial or complete remission.

7 Sep 2018

Researchers test experimental cancer vaccine on mice with aggressive melanoma

An experimental cancer vaccine that boosts the immune system's ability to fight cancers could work in tandem with other cancer therapies to fight aggressive tumors, scientists reported recently in the Proceedings of the National Academy of Sciences.

7 Sep 2018

Researchers discover reason why many bladder cancer patients do not respond to immunotherapy

Mount Sinai researchers have discovered that a particular type of cell present in bladder cancer may be the reason why so many patients do not respond to the groundbreaking class of drugs known as PD-1 and PD-L1 immune checkpoint inhibitors, which enable the immune system to attack tumors.

29 Aug 2018

New radiomic signature offers predictive score for efficacy of immunotherapy in patients

A study published in The Lancet Oncology establishes for the first time that artificial intelligence can process medical images to extract biological and clinical information.

27 Aug 2018

FDA approves Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma

Agilent Technologies Inc. today announced that the U.S. Food and Drug Administration has approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma.

22 Aug 2018

Harbour Biomed and Kelun-Biotech collaborate to develop, commercialize anti-PD-L1 antibody

Harbour BioMed today announced it has entered into an exclusive strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to develop and commercialize A167, an anti-PD-L1 antibody in Phase 2 clinical development, worldwide outside of the Greater China region.

20 Aug 2018

Cancer cells release biological 'drones' to assist in the fight against immune system

Cancer cells are more than a lump of cells growing out of control; they participate in active combat with the immune system for their own survival. Being able to evade the immune system is a hallmark of cancer.

9 Aug 2018

Blood-based test accurately identifies lung cancer patients who could benefit from immunotherapies

Researchers at UC Davis, Genentech and Foundation Medicine are the first to show that a blood-based test to assess tumor mutational burden accurately identifies non-small cell lung cancer (NSCLC) patients who could benefit from immunotherapies called checkpoint inhibitors.

7 Aug 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Scientists identify melanoma biomarkers that could help tailor immunotherapy treatments

Scientists at Dana-Farber/Brigham and Women's Cancer Center have identified biomarkers in melanoma that could help tailor immunotherapy treatments to maximize the benefits for patients while reducing the likelihood of severe side effects.

19 Jul 2018

New clinical trial to evaluate virotherapy and immunotherapy combination for ovarian, colorectal cancers

Ludwig Cancer Research and the Cancer Research Institute announce the initiation of a clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI (durvalumab) for advanced ovarian and colorectal cancers.

12 Jul 2018

PD L1 News and Research

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Immunotherapy increases survival in some patients with metastatic triple negative breast cancer

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

First-of-its-kind study to test a personalized vaccine in cancer patient

HalioDx announces availability of Brightplex, a high capacity IHC multiplex technology

New project identifies immune checkpoint inhibition as potential treatment for angiosarcomas

FDA approves first intravenous treatment for metastatic cutaneous squamous cell carcinoma

Non-small cell lung cancer patients survive longer when treated with durvalumab

Organs actively fighting back against autoimmune diseases, finds study

Immune checkpoint inhibition may be effective in treating HIV-associated Kaposi's sarcoma

Researchers test experimental cancer vaccine on mice with aggressive melanoma

Researchers discover reason why many bladder cancer patients do not respond to immunotherapy

New radiomic signature offers predictive score for efficacy of immunotherapy in patients

FDA approves Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma

Harbour Biomed and Kelun-Biotech collaborate to develop, commercialize anti-PD-L1 antibody

Cancer cells release biological 'drones' to assist in the fight against immune system

Blood-based test accurately identifies lung cancer patients who could benefit from immunotherapies

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Scientists identify melanoma biomarkers that could help tailor immunotherapy treatments

New clinical trial to evaluate virotherapy and immunotherapy combination for ovarian, colorectal cancers

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News